EU health regulator clears use of AI tool in fatty liver disease trials
March 20 (Reuters) - A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH in clinical trials to help identify the severity of a type of fatty liver disease.
The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a difficult-to-treat disease that affects around 1.5% to 6.5% of adults in the U.S., according to the American Liver Foundation.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The AI-based AIM-NASH tool employs a machine learning model trained on more than 100,000 annotations from 59 pathologists who assessed over 5,000 liver biopsies across nine large clinical trials.
The EMA's human medicines committee (CHMP) said evidence showed the AI tool can reliably determine disease activity from biopsies with less variability than the current standard in trials that rely on a consensus of three pathologists.
On that basis, the CHMP concluded, it can accept evidence generated by the tool as scientifically valid, which will help researchers obtain clearer evidence on the benefits of new treatments in clinical trials.
Currently, Madrigal Pharmaceuticals' (MDGL.O), opens new tab, Rezdiffra is the only U.S.-approved drug for MASH.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 hours ago
- Reuters
GSK says EU heath regulator reviewing expansion of RSV vaccine
June 13 (Reuters) - GSK (GSK.L), opens new tab said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age. A decision by the European Union's health regulator on the vaccine, already approved for certain age groups, is expected in the first half of 2026, GSK said.
Daily Mail
6 hours ago
- Daily Mail
UK vaccine chiefs suspend newly approved jab for over 65s - reports of two deaths and 21 severe reactions
UK vaccine chiefs have suspended a newly approved jab from being given to people aged over 65, after reports of two deaths and 21 severe reactions. The vaccine protects against the potentially fatal Chikungunya virus, which is typically found in the subtropical regions of the Americas, Africa, Southeast Asia, India, the Pacific Region and increasingly in Europe. Although the virus isn't found in the UK, Britons can become infected while overseas and fall ill when they return home. While the jab, called IXCHIQ, is approved in the UK it has yet to be rolled out, so there are no immediate safety concerns, British regulators said. The suspension follows global reports of 23 serious adverse effects in older people, including two deaths. It followed two fatalities in the French island La Réunion—in the Indian Ocean—where a vaccination campaign is underway following a recent Chikungunya outbreak. One death involved an 84-year-old man who developed encephalitis—a swelling of the brain—after having an adverse reaction to the vaccine. The other was a 77-year-old man living with Parkinson's disease who reportedly began finding swallowing increasingly difficult after the jab. This is believed to have triggered aspiration pneumonia, a serious infection caused by food, saliva and/or vomit entering the lungs rather than the stomach. The European Medicines Agency, who are reviewing the chikungunya vaccine following the reports, has not yet revealed the time between the dead men receiving the jabs and their deaths. There are no changes in the recommendations for vaccination with IXCHIQ for people aged between 18 and 64. The vaccine is currently not approved for use in individuals with a weakened immune system as a result of disease or medical therapy. The decision by the Commission on Human Medicines (CHM) is a precautionary measure until a further safety review has been concluded. The Medicines and Healthcare products Regulatory Agency (MHRA) is working with the vaccine manufacturer Valneva. The majority of people infected with Chikungunya develop a sudden fever and severe pain in multiple joints. Other symptoms may include headache, muscle pain, joint swelling, or rash. The virus is spread to humans by bites from infected mosquitoes, but cannot be passed from person-to-person. Symptoms typically resolve within 7 to 10 days, and most patients make a full recovery. However, in some cases the joint pain and arthritis may persist for several months or even years. Occasional cases of eye, neurological and heart complications have been reported, as well as gastrointestinal complaints. A small number of people may develop a severe version of the disease, which can lead to multiple organ failure and death. Severe symptoms and deaths are rare and usually occur in young babies or elderly people with coexisting health problems. There is no specific antiviral treatment for Chikungunya but medications (such as paracetamol) for fever and pain can be used to alleviate these symptoms. There are currently two vaccinations which protect against the virus; IXCHIQ for those aged between 18 and 64 and Vimkunya for those 12 years and older. A recent outbreak in La Réunion has seen over 47,500 cases of the virus, with 12 fatalities. In 2024 there were 112 Chikungunya cases reported in England, Wales and Northern Ireland from travellers arriving to or returning to Britain—this was nearly one-and-a-half times the level recorded in the previous year.
Reuters
13 hours ago
- Reuters
US health chief says Sen. Cassidy promised pick on vaccine panel
WASHINGTON, June 12 (Reuters) - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said he told U.S. Senator Bill Cassidy that he would allow Cassidy to pick a candidate for a key panel of vaccine advisers. Cassidy, a Republican, serves as chairman the U.S. Senate Health, Education, Labor, and Pensions Committee. "What I told Senator Cassidy is that I would allow him to put one of his candidates on, which we're going to do," Kennedy said on Thursday during an interview on Fox News' "The Story with Martha MacCallum," referring to the vaccine advisory panel. Kennedy on Wednesday named eight members to serve on the U.S. Centers for Disease Control and Prevention's Advisory Committee for Immunization Practices, which advises the agency on who should get the shots after they are approved by the U.S. Food and Drug Administration, after gutting the panel last week.
